Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with debilitating diseases, announced today that the first patient has been dosed at the Cystic Fibrosis Institute of Chicago in the Company’s Phase 1 CORAL-1/US study evaluating KB407, an engineered HSV-1-based, aerosol-delivered, mutation agnostic, genetic medicine for the treatment of patients with cystic fibrosis (CF).
https://www.marketscreener.com/quote/stock/KRYSTAL-BIOTECH-INC-37797982/news/Krystal-Biotech-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-KB407-for-the-Treatment-o-44252085/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.